Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Josep TaberneroJean-Charles Soria

Abstract

JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. This first-in-human study evaluates the safety, pharmacokinetics, and pharmacodynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493. Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off). Sixty-five patients were enrolled. The most common treatment-emergent adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%). Twenty-seven patients (42%) experienced grade ≥ 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was observed at 12 mg daily. Maximum-tolerated dose was not defined. Nine milligrams daily was considered as the initial RP2D; however, tolerability was improved with intermittent schedules, and 10 mg administered on a 7-days-on/7-days-off schedule was considered the final RP2D. Pharmacokinetics were linear, dose proportional, and predictable, with a half-life of 50 to 60 hours. Dos...Continue Reading

References

Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joachim DrevsClemens Unger
Apr 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Debashis SarkerJohann S de Bono
Jan 13, 2009·Journal of Environmental Monitoring : JEM·Silvana AndreescuMatthew T Ravalli
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabrice AndreLajos Pusztai
Feb 28, 2009·Nature Reviews. Drug Discovery·Andrew Beenken, Moosa Mohammadi
Jan 23, 2010·Nature Reviews. Cancer·Nicholas Turner, Richard Grose
Dec 7, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J JonkerS Galbraith
Jun 30, 2011·The Biochemical Journal·Jørgen WescheEllen Margrethe Haugsten
May 10, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabrice AndréJosé Baselga
Nov 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R DienstmannJ Tabernero
Mar 4, 2014·The Journal of Pathology·Brittany C ParkerWei Zhang
Apr 3, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bernard EscudierEric Angevin
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R DienstmannJ Tabernero

❮ Previous
Next ❯

Citations

Jan 20, 2016·Expert Review of Anticancer Therapy·Katrin SchlackLaura-Maria Krabbe
Dec 10, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A W TolcherP M LoRusso
Mar 1, 2016·Future Oncology·Ana Collazo-Lorduy, Matthew D Galsky
Mar 24, 2016·Pharmacology & Therapeutics·Zhuo Li, Yibin Kang
Feb 14, 2015·Journal of Gastroenterology and Hepatology·Celina Ang
Apr 22, 2016·Journal of Cancer Research and Clinical Oncology·Niklas SchäferMartin Glas
Mar 15, 2016·Expert Opinion on Biological Therapy·Camille Sibertin-BlancJean-François Seitz
Jun 18, 2016·Cancer·Paul K Paik, Charles M Rudin
Jul 7, 2016·Future Oncology·Erica di MartinoMargaret A Knowles
Sep 15, 2016·PloS One·Terence G HallGiovanni Abbadessa
Oct 18, 2016·European Journal of Medicinal Chemistry·Yang LiuYouhong Hu
Jan 26, 2017·Expert Opinion on Investigational Drugs·Antonella De LucaNicola Normanno
Sep 2, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy Lewin, Lillian L Siu
May 11, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth R Plimack, Daniel M Geynisman
Mar 10, 2017·Expert Opinion on Investigational Drugs·Elaine ShumHaiying Cheng
Mar 21, 2017·Acta Pharmacologica Sinica·Y RajeshMahitosh Mandal
Apr 8, 2017·Expert Opinion on Investigational Drugs·Erika RijavecFrancesco Grossi
Apr 6, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yan ZhangBing Xiong
Mar 23, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C HierroJ Tabernero
May 5, 2017·Developmental Dynamics : an Official Publication of the American Association of Anatomists·N S ClaytonE P Carter
Apr 9, 2017·Journal of Hepatology·Sumera Rizvi, Gregory J Gores
Jun 18, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Laura LeroyAntoine Italiano
Nov 20, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Sang Hee ChoIk Joo Chung
Oct 27, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zhen ZhangBing Xiong
Mar 29, 2018·Cold Spring Harbor Molecular Case Studies·Jatinder DhamiLorna Rodriguez-Rodriguez
Oct 4, 2017·British Journal of Cancer·K P PapadopoulosW L Shaib
Sep 1, 2017·Nature Reviews. Clinical Oncology·Alison M SchramAlexander Drilon
Sep 28, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Sebastien TaurinMargit M Janát-Amsbury
Jun 26, 2018·Expert Review of Anticancer Therapy·Gaia Cristina GhediniArianna Giacomini
Aug 2, 2018·Future Medicinal Chemistry·Wen-Jun XueYu-Yan Li
Jul 26, 2018·The Journal of Pathology·Mona FothTomoko Iwata
Oct 17, 2018·Future Medicinal Chemistry·Nestor Prieto-DominguezYong Teng
Jul 18, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Iyer, J E Rosenberg
Oct 28, 2018·Nature Reviews. Clinical Oncology·Masaru Katoh
Oct 31, 2018·International Journal of Clinical Oncology·Aristotelis BamiasMeletios-Athanasios Dimopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.